Cargando…
5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer
BACKGROUND: Depicting the heterogeneity and functional characteristics of the tumor microenvironment (TME) is necessary to achieve precision medicine for bladder cancer (BLCA). Although classical molecular subtypes effectively reflect TME heterogeneity and characteristics, their clinical application...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627095/ https://www.ncbi.nlm.nih.gov/pubmed/34836536 http://dx.doi.org/10.1186/s12916-021-02163-6 |
_version_ | 1784606787934093312 |
---|---|
author | Hu, Jiao Othmane, Belaydi Yu, Anze Li, Huihuang Cai, Zhiyong Chen, Xu Ren, Wenbiao Chen, Jinbo Zu, Xiongbing |
author_facet | Hu, Jiao Othmane, Belaydi Yu, Anze Li, Huihuang Cai, Zhiyong Chen, Xu Ren, Wenbiao Chen, Jinbo Zu, Xiongbing |
author_sort | Hu, Jiao |
collection | PubMed |
description | BACKGROUND: Depicting the heterogeneity and functional characteristics of the tumor microenvironment (TME) is necessary to achieve precision medicine for bladder cancer (BLCA). Although classical molecular subtypes effectively reflect TME heterogeneity and characteristics, their clinical application is limited by several issues. METHODS: In this study, we integrated the Xiangya cohort and multiple external BLCA cohorts to develop a novel 5-methylcytosine (5mC) regulator-mediated molecular subtype system and a corresponding quantitative indicator, the 5mC score. Unsupervised clustering was performed to identify novel 5mC regulator-mediated molecular subtypes. The principal component analysis was applied to calculate the 5mC score. Then, we correlated the 5mC clusters (5mC score) with classical molecular subtypes, immunophenotypes, clinical outcomes, and therapeutic opportunities in BLCA. Finally, we performed pancancer analyses on the 5mC score. RESULTS: Two 5mC clusters, including 5mC cluster 1 and cluster 2, were identified. These novel 5mC clusters (5mC score) could accurately predict classical molecular subtypes, immunophenotypes, prognosis, and therapeutic opportunities of BLCA. 5mC cluster 1 (high 5mC score) indicated a luminal subtype and noninflamed phenotype, characterized by lower anticancer immunity but better prognosis. Moreover, 5mC cluster 1 (high 5mC score) predicted low sensitivity to cancer immunotherapy, neoadjuvant chemotherapy, and radiotherapy, but high sensitivity to antiangiogenic therapy and targeted therapies, such as blocking the β-catenin, FGFR3, and PPAR-γ pathways. CONCLUSIONS: The novel 5mC regulator-based subtype system reflects many aspects of BLCA biology and provides new insights into precision medicine in BLCA. Furthermore, the 5mC score may be a generalizable predictor of immunotherapy response and prognosis in pancancers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-021-02163-6. |
format | Online Article Text |
id | pubmed-8627095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86270952021-11-30 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer Hu, Jiao Othmane, Belaydi Yu, Anze Li, Huihuang Cai, Zhiyong Chen, Xu Ren, Wenbiao Chen, Jinbo Zu, Xiongbing BMC Med Research Article BACKGROUND: Depicting the heterogeneity and functional characteristics of the tumor microenvironment (TME) is necessary to achieve precision medicine for bladder cancer (BLCA). Although classical molecular subtypes effectively reflect TME heterogeneity and characteristics, their clinical application is limited by several issues. METHODS: In this study, we integrated the Xiangya cohort and multiple external BLCA cohorts to develop a novel 5-methylcytosine (5mC) regulator-mediated molecular subtype system and a corresponding quantitative indicator, the 5mC score. Unsupervised clustering was performed to identify novel 5mC regulator-mediated molecular subtypes. The principal component analysis was applied to calculate the 5mC score. Then, we correlated the 5mC clusters (5mC score) with classical molecular subtypes, immunophenotypes, clinical outcomes, and therapeutic opportunities in BLCA. Finally, we performed pancancer analyses on the 5mC score. RESULTS: Two 5mC clusters, including 5mC cluster 1 and cluster 2, were identified. These novel 5mC clusters (5mC score) could accurately predict classical molecular subtypes, immunophenotypes, prognosis, and therapeutic opportunities of BLCA. 5mC cluster 1 (high 5mC score) indicated a luminal subtype and noninflamed phenotype, characterized by lower anticancer immunity but better prognosis. Moreover, 5mC cluster 1 (high 5mC score) predicted low sensitivity to cancer immunotherapy, neoadjuvant chemotherapy, and radiotherapy, but high sensitivity to antiangiogenic therapy and targeted therapies, such as blocking the β-catenin, FGFR3, and PPAR-γ pathways. CONCLUSIONS: The novel 5mC regulator-based subtype system reflects many aspects of BLCA biology and provides new insights into precision medicine in BLCA. Furthermore, the 5mC score may be a generalizable predictor of immunotherapy response and prognosis in pancancers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-021-02163-6. BioMed Central 2021-11-26 /pmc/articles/PMC8627095/ /pubmed/34836536 http://dx.doi.org/10.1186/s12916-021-02163-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Hu, Jiao Othmane, Belaydi Yu, Anze Li, Huihuang Cai, Zhiyong Chen, Xu Ren, Wenbiao Chen, Jinbo Zu, Xiongbing 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer |
title | 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer |
title_full | 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer |
title_fullStr | 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer |
title_full_unstemmed | 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer |
title_short | 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer |
title_sort | 5mc regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627095/ https://www.ncbi.nlm.nih.gov/pubmed/34836536 http://dx.doi.org/10.1186/s12916-021-02163-6 |
work_keys_str_mv | AT hujiao 5mcregulatormediatedmolecularsubtypesdepictthehallmarksofthetumormicroenvironmentandguideprecisionmedicineinbladdercancer AT othmanebelaydi 5mcregulatormediatedmolecularsubtypesdepictthehallmarksofthetumormicroenvironmentandguideprecisionmedicineinbladdercancer AT yuanze 5mcregulatormediatedmolecularsubtypesdepictthehallmarksofthetumormicroenvironmentandguideprecisionmedicineinbladdercancer AT lihuihuang 5mcregulatormediatedmolecularsubtypesdepictthehallmarksofthetumormicroenvironmentandguideprecisionmedicineinbladdercancer AT caizhiyong 5mcregulatormediatedmolecularsubtypesdepictthehallmarksofthetumormicroenvironmentandguideprecisionmedicineinbladdercancer AT chenxu 5mcregulatormediatedmolecularsubtypesdepictthehallmarksofthetumormicroenvironmentandguideprecisionmedicineinbladdercancer AT renwenbiao 5mcregulatormediatedmolecularsubtypesdepictthehallmarksofthetumormicroenvironmentandguideprecisionmedicineinbladdercancer AT chenjinbo 5mcregulatormediatedmolecularsubtypesdepictthehallmarksofthetumormicroenvironmentandguideprecisionmedicineinbladdercancer AT zuxiongbing 5mcregulatormediatedmolecularsubtypesdepictthehallmarksofthetumormicroenvironmentandguideprecisionmedicineinbladdercancer |